Eiropas Savienība -
portugāļu -
EMA (European Medicines Agency)
alunbrig
takeda pharma a/s - brigatinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
Brazīlija -
portugāļu -
ANVISA (Agência Nacional de Vigilância Sanitária)
evobrig
takeda pharma ltda. - brigatinibe - outros agentes antineoplÁsicos
Brazīlija -
portugāļu -
ANVISA (Agência Nacional de Vigilância Sanitária)
lorbrena
pfizer brasil ltda - lorlatinibe - agentes antineoplÁsicos